Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

US Endocrinology - United Kingdom
doi 10.17925/use.2017.13.02.75
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Touch Medical Media, Ltd.

Related search

Early Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes: Study Based on Continuous Glucose Monitoring

Diabetology and Metabolic Syndrome
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Sodium-Glucose Co-Transporter 2 Inhibitors: A Review of Their Use in Older People With Type 2 Diabetes Mellitus

Journal of Pharmacy Practice and Research
PharmacologyPharmacy
2016English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?

Anaesthesia
AnesthesiologyPain Medicine
2019English

Sodium-Glucose Co-Transporter Type-2 Inhibitors: Pharmacology and Peri-Operative Considerations

Anaesthesia
AnesthesiologyPain Medicine
2018English

The Potential Role of Sodium Glucose Co-Transporter 2 Inhibitors in the Early Treatment of Type 2 Diabetes Mellitus

International Journal of Clinical Practice
Medicine
2015English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through? A Reply

Anaesthesia
AnesthesiologyPain Medicine
2019English

Should Sodium Glucose Co-Transporter 2 Inhibitors Be Considered as First Line Oral Therapy for People With Type 2 Diabetes?

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis

2018English

Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Drugs in Context
Molecular MedicinePharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy